Reduced serum corin levels in patients with osteoporosis

Clinica Chimica Acta

Volumn 426, Issue , 2013, Pages 152-156

  Zhou, Haibin ^a   Liu, Wei ^a   Zhu, Jinsong ^a   Liu, Meng ^b   Fang, Chaodong ^b   Wu, Qingyu ^b,c   Dong, Ningzheng ^b,d  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c LERNER RESEARCH INSTITUTE   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Bone; Corin; Osteocalcin; Osteopenia; Osteoporosis

Indexed keywords

CORIN; OSTEOCALCIN; PROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORIN BLOOD LEVEL; DISEASE ASSOCIATION; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOCALCIN BLOOD LEVEL; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

3,3′,5,5′-TETRAMETHYLBENZIDINE; BMD; BONE; BONE MINERAL DENSITY; CORIN; FEMORAL NECK; FN; HMSCS; HUMAN MESENCHYMAL STEM CELLS; LS; LUMBAR SPINE; OSTEOCALCIN; OSTEOPENIA; OSTEOPOROSIS; TMB;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; SERINE ENDOPEPTIDASES;

EID: 84885360332     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.09.007     Document Type: Article

References (46)

1. Bessette L., Davison K.S., Jean S., Roy S., Ste-Marie L.G., Brown J.P. The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized controlled trial. Osteoporos Int 2011, 22:2963-2972.
2. Blake G.M., Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 2007, 10:102-110.
3. Leslie W.D., Schousboe J.T. A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Curr Osteoporos Rep 2011, 9:129-140.
4. MacLaughlin E.J. Improving osteoporosis screening, risk assessment, diagnosis, and treatment initiation: role of the health-system pharmacist in closing the gap. Am J Health Syst Pharm 2010, 67:S4-S8.
5. Watts N.B., Bilezikian J.P., Camacho P.M., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract 2010, 16:1016-1019.
6. Gass M., Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 2006, 119:S3-S11.
7. Das S., Crockett J.C. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther 2013, 7:435-448.
8. Ebeling P.R., Faienza M.F., Ventura A., Marzano F., Cavallo L. Osteoporosis in men: the role of immune system cells. Curr Opin Rheumatol 2013, 25:542-552.
9. Hooper J.D., Scarman A.L., Clarke B.E., Normyle J.F., Antalis T.M. Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem 2000, 267:6931-6937.
10. Wu F., Yan W., Pan J., Morser J., Wu Q. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem 2002, 277:16900-16905.
11. Wu Q. The serine protease corin in cardiovascular biology and disease. Front Biosci 2007, 12:4179-4190.
12. Yan W., Sheng N., Seto M., Morser J., Wu Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem 1999, 274:14926-14935.
13. Potter L.R., Abbey-Hosch S., Dickey D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006, 27:47-72.
14. Wu Q., Xu-Cai Y.O., Chen S., Wang W. Corin: new insights into the natriuretic peptide system. Kidney Int 2009, 75:142-146.
15. Yan W., Wu F., Morser J., Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 2000, 97:8525-8529.
16. Cui Y., Wang W., Dong N., et al. Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. Nature 2012, 484:246-250.
17. Kaitu'u-Lino T.J., Ye L., Tuohey L., et al. Corin, an enzyme with a putative role in spiral artery remodeling, is up-regulated in late secretory endometrium and first trimester decidua. Hum Reprod 2013, 28:1172-1180.
18. Zhou Y., Wu Q. Role of corin and atrial natriuretic peptide in preeclampsia. Placenta 2013, 34:89-94.
19. Knappe S., Wu F., Madlansacay M.R., Wu Q. Identification of domain structures in the propeptide of corin essential for the processing of proatrial natriuretic peptide. J Biol Chem 2004, 279:34464-34471.
20. Liao X., Wang W., Chen S., Wu Q. Role of glycosylation in corin zymogen activation. J Biol Chem 2007, 282:27728-27735.
21. Qi X., Jiang J., Zhu M., Wu Q. Human corin isoforms with different cytoplasmic tails that alter cell surface targeting. J Biol Chem 2011, 286:20963-20969.
22. Garton K.J., Gough P.J., Raines E.W. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol 2006, 79:1105-1116.
23. Jiang J., Wu S., Wang W., et al. Ectodomain shedding and autocleavage of the cardiac membrane protease corin. J Biol Chem 2011, 286:10066-10072.
24. Wu Q. Type II transmembrane serine proteases. Curr Top Dev Biol 2003, 54:167-206.
25. Dong N., Chen S., Wang W., Zhou Y., Wu Q. Corin in clinical laboratory diagnostics. Clin Chim Acta 2012, 413:378-383.
26. Dong N., Dong J., Liu P., Xu L., Shi S., Wu Q. Effects of anticoagulants on human plasma soluble corin levels measured by ELISA. Clin Chim Acta 2010, 411:1998-2003.
27. Dong N., Fang C., Jiang Y., et al. Corin mutation R539C from hypertensive patients impairs zymogen activation and generates an inactive alternative ectodomain fragment. J Biol Chem 2013, 288:7867-7874.
28. Ichiki T., Huntley B.K., Heublein D.M., et al. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem 2011, 57:40-47.
29. Peleg A., Jaffe A.S., Hasin Y. Enzyme-linked immunoabsorbent assay for detection of human serine protease corin in blood. Clin Chim Acta 2009, 409:85-89.
30. Dong N., Chen S., Yang J., et al. Plasma soluble corin in patients with heart failure. Circ Heart Fail 2010, 3:207-211.
31. Ibebuogu U.N., Gladysheva I.P., Houng A.K., Reed G.L. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ Heart Fail 2011, 2011:114-120.
32. Peleg A., Ghanim D., Vered S., Hasin Y. Serum corin is reduced and predicts adverse outcome in non-ST-elevation acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 2013, 2:159-165.
33. Enshell-Seijffers D., Lindon C., Morgan B.A. The serine protease Corin is a novel modifier of the Agouti pathway. Development 2008, 135:217-225.
34. Fang C., Shen L., Dong L., et al. Reduced urinary corin levels in patients with chronic kidney disease. Clin Sci (Lond) 2013, 124:709-717.
35. Polzin D., Kaminski H.J., Kastner C., et al. Decreased renal corin expression contributes to sodium retention in proteinuric kidney diseases. Kidney Int 2010, 78:650-659.
36. Charoenpanich A., Wall M.E., Tucker C.J., Andrews D.M., Lalush D.S., Loboa E.G. Microarray analysis of human adipose-derived stem cells in three-dimensional collagen culture: osteogenesis inhibits bone morphogenic protein and Wnt signaling pathways, and cyclic tensile strain causes upregulation of proinflammatory cytokine regulators and angiogenic factors. Tissue Eng Part A 2011, 17:2615-2627.
37. Liu T.M., Martina M., Hutmacher D.W., Hui J.H., Lee E.H., Lim B. Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells 2007, 25:750-760.
38. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994, 4:368-381.
39. Chen S., Sen S., Young D., Wang W., Moravec C.S., Wu Q. Protease corin expression and activity in failing hearts. Am J Physiol Heart Circ Physiol 2010, 299:H1687-H1692.
40. Cremers S., Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 2006, 66:2031-2058.
41. Claudon A., Vergnaud P., Valverde C., Mayr A., Klause U., Garnero P. New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem 2008, 54:1554-1563.
42. Garnero P., Vergnaud P., Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008, 54:188-196.
43. Samoszuk M., Leuther M., Hoyle N. Role of serum P1NP measurement for monitoring treatment response in osteoporosis. Biomark Med 2008, 2:495-508.
44. Halleen J.M., Alatalo S.L., Janckila A.J., Woitge H.W., Seibel M.J., Vaananen H.K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2001, 47:597-600.
45. Biver E. Use of bone turnover markers in clinical practice. Curr Opin Endocrinol Diabetes Obes 2012, 19:468-473.
46. Boyce B.F., Rosenberg E., de Papp A.E., Duong le T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur J Clin Invest 2012, 42:1332-1341.